Roche Holding AG (RHHBF)
| Market Cap | 378.38B +33.9% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.61 +30.6% |
| Shares Out | n/a |
| PE Ratio | 26.48 |
| Forward PE | n/a |
| Dividend | 12.41 (2.52%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 5 |
| Open | 492.81 |
| Previous Close | 480.00 |
| Day's Range | 492.81 - 492.81 |
| 52-Week Range | 301.27 - 514.08 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 28, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Roche's Divarasib Cuts Death Risk By 44% In KRAS G12C-Mutated Lung Cancer Phase III Trial
(RTTNews) - Roche Holding AG (RHHBY) announced positive pivotal results from its Phase III Krascendo 1 study, showing that investigational therapy divarasib significantly outperformed currently approv...
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
The Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company's first shot at an emerging field within the oncology mark...
Roche's Divarasib Boosts Lung Cancer Survival, RHHBY Dividend Remains Solid Amid Valuation Concerns
Roche's Divarasib Boosts Lung Cancer Survival, RHHBY Dividend Remains Solid Amid Valuation Concerns
Genentech says Phase III Krascendo 1 study met primary, secondary endpoints
Genentech, a member of the Roche (RHHBY) Group, announced results from the Phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G1...
Roche says divarasib cut risk of death 44% in lung cancer trial
Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced the risk of death by 44% compared with existing treatments in a phase III study.
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung c...
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib,...
Roche Reports Positive Phase III Data For Investigational IgAN Therapy Sefaxersen
(RTTNews) - Roche (RHHBY) announced new late-breaking data from the ongoing Phase III IMAgINATION study showing that its investigational therapy sefaxersen delivered a statistically significant and cl...
Zymeworks price target raised to $52 from $50 at Jefferies
Jefferies raised the firm’s price target on Zymeworks (ZYME) to $52 from $50 and keeps a Buy rating on the shares. The company and Roche (RHHBY) entered into an exclusive…
Ionis Pharmaceuticals, Inc. Partner Roche Announces Positive Phase 3 IMAgINATION Data for Sefaxersen in IgA Nephropathy
On October 23, 2026, Ionis Pharmaceuticals, Inc. issued a press release reporting that its partner, Roche, announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in ...
Roche says Sefaxersen trial shows meaningful reduction in proteinuria
Ionis Pharmaceuticals (IONS) partner Roche (RHHBY) announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy receiving optimized ...
Roche reports Sefaxersen achieved 43.1% reduction in proteinuria in trial
Roche (RHHBY) announced late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy receiving optimized standard of care, demonstrating tha...
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today late-breaking oral presentation data from the ongoing Phase III IMAgI...
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (Ig...
Zymeworks Licenses Cancer Drug Candidate ZW209 To Roche In Deal Worth Up To $813 Million
(RTTNews) - Zymeworks (ZYME) has entered into an exclusive global license and collaboration agreement with Roche (RHHBY) for ZW209, a trispecific T-cell engager being developed for cancers that expres...
Zymeworks signs collaboration and license agreement with Roche for ZW209
Zymeworks (ZYME) announced that it has entered into a global license and collaboration agreement with Roche (RHHBY) for the research, development and commercialization of ZW209, a T cell engager targe...
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
Zymeworks said on Friday Roche has gained rights to develop and commercialize its experimental lung cancer drug under a global licensing deal worth up to $813 million.
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sale...
Roche upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Roche (RHHBY) to Buy from Hold with a price target of CHF 500, up from CHF 340, post the Q3 report. The firm says physician feedback on…
Q3 2026 Roche Holding AG Corporate Sales Call Transcript
Q3 2026 Roche Holding AG Corporate Sales Call Transcript
Roche, In A Buy Zone, Matches Revenue Forecasts Despite Light Pharma Sales
Roche stock was unmoved early Thursday after the drugmaker matched sales expectations despite light pharma sales.
Roche Holding AG Earnings Call Transcript: Q3 2026
YTD sales rose 6% at CER, with Pharma growth offsetting Diagnostics pricing pressure in China; Q3 included a temporary Japan shipment-timing benefit. Guidance was reaffirmed, with margins expected to expand next year and pipeline progress supporting growth into 2030.
Roche Holding AG Earnings release: Q3 2026
Roche Holding AG released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Roche Holding AG Slides: Q3 2026
Roche Holding AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Roche reports 9M group sales CHF 46.5B vs. CHF 45.9B last year
In the first nine months of 2026, Roche (RHHBY) sales were +6% at CER, +1% when reported in CHF, to CHF 46.5B due to strong demand for pharmaceutical products and…